Interventional cardiology news to note
The Stellarex low-dose drug-coated balloon showed safety and efficacy out to 3 years in the ILLUMENATE pivotal trial and the ILLUMENATE European trial. Mortality rates of 10.1% and 9.4%, respectively, didn't differ significantly from uncoated balloon control groups, according to Philips.
Acute kidney injury risk with transcatheter aortic valve replacement (TAVR) wasn't reduced by forced diuresis with matched hydration in the sham-controlled REDUCE-AKI trial, investigators reported in the European Heart Journal.
Three years after valve-in-valve TAVR for a degenerated bioprosthesis, gradients remained low and effective orifice areas large among high-risk patients in the PARTNER 2 registry. Researchers also noted sustained reductions in aortic, mitral, and tricuspid regurgitation, as well as improvements in quality of life. (Journal of the American College of Cardiology)
Perceived and calculated bleeding risk were only modestly correlated in an Italian percutaneous coronary intervention registry comparing four risk-calculating scores. The proportion at high bleeding risk doubled with some calculators compared with perceived (uncalculated) risk. (Circulation: Cardiovascular Interventions)
In stable coronary artery disease, 3-year outcomes of lesions deferred for revascularization on the basis of fractional flow reserve may hinge on LDL cholesterol, researchers reported in Catheterization & Cardiovascular Interventions.
Intermittent claudication from peripheral artery disease improves most in terms of walking distance and quality of life when treated with percutaneous angioplasty on top of supervised exercise therapy, a meta-analysis in JACC: Cardiovascular Interventionsconcluded.
The first study of a transcatheter device designed to improve left ventricular function is underway in patients with heart failure with reduced ejection fraction, Ancora Heart announced.
Read the original article on Medpage Today: Low-Dose DCB Prevails; ViV TAVR at 3 Years; LDL vs Lesion Stability